Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc episode artwork

EPISODE · Jan 28, 2022 · 5 MIN

Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc

from Oncology Data Advisor · host i3 Health

Tumor suppressor gene p53 is the most frequently mutated gene in human malignancy. Through a complex series of molecular events, p53 leads to malignant cell proliferation and plays a significant role in tumor formation. In this interview with Oncology Data Advisor, Dr. Matthew Davids of Harvard Medical School delves further into the latest research in p53-directed therapeutic strategies and the future of targeting this specific mutation.

Episode metadata supplied by the publisher feed · Published Jan 28, 2022

Embed this episode

NOW PLAYING

Targeting p53 in the Treatment of Hematologic Malignancies With Matthew Davids, MD, MMSc

0:00 5:35

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Oncology Data Advisor?

This episode is 5 minutes long.

When was this Oncology Data Advisor episode published?

This episode was published on January 28, 2022.

Can I download this Oncology Data Advisor episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!